Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
June 03, 2024 16:05 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
Publication relative à des notifications de transparence
June 03, 2024 16:05 ET
|
Nyxoah
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 3 juin 2024, 22:05h CET / 16:05h ET – Conformément à l'article 14 de la loi du...
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
June 03, 2024 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2024 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
Lavoro Reports Fiscal Third Quarter 2024 Earnings Results¹
June 03, 2024 16:05 ET
|
Lavoro Limited
3Q24 revenue grew 6% to $514.2 million. Growth was driven by continued market share gains and volume growth, which mitigated ongoing deflation in input prices throughout Brazil and Colombia.Gross...
Kernel Group Holdings, Inc. Extends Period to Consummate Initial Business Combination
June 03, 2024 16:05 ET
|
Kernel Group Holdings, Inc
New York, June 03, 2024 (GLOBE NEWSWIRE) -- Kernel Group Holdings, Inc. (NASDAQ: KRNLU, KRNL, KRNLW) (“KRNL” or the “Company”), a special purpose acquisition company, announced today that it has...
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
June 03, 2024 16:05 ET
|
FibroGen, Inc.
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to...
Dave Extends its Partnership with Drew League, LA’s Pro-Am Basketball League
June 03, 2024 16:05 ET
|
Dave Operating LLC
LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- Dave (NASDAQ: DAVE), one of the nation's leading neobanks, announced an extension of its official partnership with the Drew League, Los Angeles'...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2024 16:05 ET
|
X4 Pharmaceuticals
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective...
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
June 03, 2024 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official...